{ "run": { "id": "cmnr144av0488p658z3pgf0fh", "region": "US", "assetId": "cmnr143xe0482p658t6o6tyru", "ticker": "HOLX", "snapshotId": "cmnr1444d0484p658dpfiamju", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:21:02.405Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr1444d0484p658dpfiamju", "assetId": "cmnr143xe0482p658t6o6tyru", "asOf": "2026-04-06T20:00:02.000Z", "snapshot": { "asOf": "2026-04-06T20:00:02.000Z", "quote": { "asOf": "2026-04-06T20:00:02.000Z", "open": null, "price": 76.01, "dayLow": 76, "volume": 101956189, "dayHigh": 76.04, "currency": "USD", "prevClose": 76.01, "week52Low": 51.9, "week52High": 76.07 }, "fundamentals": { "pe": 24.1253731343284, "beta": 0.754611615644118, "epsTTM": 3.35, "fcfTTM": 1054700000, "growth": { "epsYoy": 0.8108108108108107, "revenueYoy": 0.02344207853096308 }, "sector": "X-Ray Apparatus & Tubes & Related Irradiation Apparatus", "margins": { "net": 0.1709295667112044, "gross": 0.5596487879366291, "operating": 0.2261882038556977 }, "website": "https://www.hologic.com/", "industry": "Medical Technology", "pegRatio": 0.297546268656716, "ebitdaTTM": 1259200000, "forwardPe": 19.2887828162291, "marketCap": 13566017923, "totalCash": 2168000000, "totalDebt": 2514500000, "debtEquity": 0.501384015594542, "quickRatio": 3.099863344896458, "revenueTTM": 1047800000, "companyName": "HOLOGIC INC", "priceToBook": 2.3465454081884, "currentRatio": 4.040155576579417, "dividendYield": null, "returnOnAssets": 0.01950831635931901, "returnOnEquity": 0.153898635477583, "analystOpinions": null, "businessSummary": "Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.", "enterpriseValue": 19463032860, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 7070, "sharesOutstanding": 223244905, "enterpriseToEbitda": 15.45666523189326, "analystTargetMedian": null, "enterpriseToRevenue": 18.57514111471655, "operatingCashflowTTM": 229900000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:21:02.173Z" }, "results": [ { "id": "cmnr144ay048ap658hln24xr7", "runId": "cmnr144av0488p658z3pgf0fh", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-06T20:00:02.000Z\",\"ticker\":\"HOLX\",\"currency\":\"USD\",\"current_price\":76.01,\"target_price_6m\":81.0,\"target_price_12m\":84.5,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Attractive PEG ratio of 0.30 signals undervaluation relative to earnings growth\",\"Strong FCF generation of ~$1.05B supports buybacks and deleveraging\",\"Women's health focus provides defensive moat in medical technology\",\"Margin expansion runway from 22.6% operating to mid-20s achievable\",\"Near 52-week high limits near-term upside; growth deceleration risk remains\"],\"key_drivers\":[{\"driver\":\"EPS growth momentum (81% YoY) driven by margin and buybacks\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Strong free cash flow conversion supporting capital returns\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Forward P/E of 19.3x reasonable for med-tech compounder\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Modest organic revenue growth of only 2.3% YoY\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Healthy balance sheet with quick ratio >3x and manageable leverage\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Potential M&A in women's health adjacencies\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Stock near 52-week high may limit near-term multiple expansion\",\"impact\":\"LOW\",\"direction\":\"NEG\"},{\"driver\":\"Regulatory and reimbursement risk in diagnostics/imaging\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Revenue growth stalls below 2% as screening volumes plateau\",\"Margin compression from pricing pressure in diagnostics segment\",\"Integration risk from potential acquisitions diluting returns\",\"Tariff or supply chain disruption affecting device margins\",\"Key product concentration risk in breast health and molecular diagnostics\"],\"assumptions\":{\"revenue_cagr_3y\":0.045,\"ebit_margin_target\":0.255,\"wacc\":0.09,\"terminal_multiple\":18.0},\"scenarios\":{\"bear\":{\"target_price\":62.0,\"prob\":0.2,\"notes\":\"Revenue declines, margin compression, multiple contracts to ~16x forward earnings.\"},\"base\":{\"target_price\":84.5,\"prob\":0.55,\"notes\":\"Mid-single-digit revenue growth, margin expansion to ~25%, ~21x forward EPS.\"},\"bull\":{\"target_price\":98.0,\"prob\":0.25,\"notes\":\"New product acceleration, accretive M&A, multiple expands to ~24x forward EPS.\"}},\"method_notes\":\"Blended valuation using forward P/E (19-22x on ~$3.95 forward EPS) and EV/EBITDA (15-18x). PEG of 0.30 supports undervaluation thesis but tempered by modest top-line growth (~2.3% YoY). Snapshot revenueTTM appears to reflect quarterly data; analysis cross-referenced typical ~$4B annual run rate. Probability-weighted scenario price ~$83.5 aligns with base target. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-06T20:00:02.000Z", "model": "ai-equity-research-v1", "risks": [ "Revenue growth stalls below 2% as screening volumes plateau", "Margin compression from pricing pressure in diagnostics segment", "Integration risk from potential acquisitions diluting returns", "Tariff or supply chain disruption affecting device margins", "Key product concentration risk in breast health and molecular diagnostics" ], "ticker": "HOLX", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Mid-single-digit revenue growth, margin expansion to ~25%, ~21x forward EPS.", "target_price": 84.5 }, "bear": { "prob": 0.2, "notes": "Revenue declines, margin compression, multiple contracts to ~16x forward earnings.", "target_price": 62 }, "bull": { "prob": 0.25, "notes": "New product acceleration, accretive M&A, multiple expands to ~24x forward EPS.", "target_price": 98 } }, "confidence": 0.62, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.045, "terminal_multiple": 18, "ebit_margin_target": 0.255 }, "key_drivers": [ { "driver": "EPS growth momentum (81% YoY) driven by margin and buybacks", "impact": "HIGH", "direction": "POS" }, { "driver": "Strong free cash flow conversion supporting capital returns", "impact": "HIGH", "direction": "POS" }, { "driver": "Forward P/E of 19.3x reasonable for med-tech compounder", "impact": "MED", "direction": "POS" }, { "driver": "Modest organic revenue growth of only 2.3% YoY", "impact": "MED", "direction": "NEG" }, { "driver": "Healthy balance sheet with quick ratio >3x and manageable leverage", "impact": "MED", "direction": "POS" }, { "driver": "Potential M&A in women's health adjacencies", "impact": "MED", "direction": "POS" }, { "driver": "Stock near 52-week high may limit near-term multiple expansion", "impact": "LOW", "direction": "NEG" }, { "driver": "Regulatory and reimbursement risk in diagnostics/imaging", "impact": "MED", "direction": "NEG" } ], "method_notes": "Blended valuation using forward P/E (19-22x on ~$3.95 forward EPS) and EV/EBITDA (15-18x). PEG of 0.30 supports undervaluation thesis but tempered by modest top-line growth (~2.3% YoY). Snapshot revenueTTM appears to reflect quarterly data; analysis cross-referenced typical ~$4B annual run rate. Probability-weighted scenario price ~$83.5 aligns with base target. Not investment advice.", "current_price": 76.01, "recommendation": "BUY", "thesis_bullets": [ "Attractive PEG ratio of 0.30 signals undervaluation relative to earnings growth", "Strong FCF generation of ~$1.05B supports buybacks and deleveraging", "Women's health focus provides defensive moat in medical technology", "Margin expansion runway from 22.6% operating to mid-20s achievable", "Near 52-week high limits near-term upside; growth deceleration risk remains" ], "target_price_6m": 81, "target_price_12m": 84.5 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 40660, "createdAt": "2026-04-09T05:21:02.405Z", "usage": { "inputTokens": 3552, "outputTokens": 1862, "costUsd": 0.06431 } }, { "id": "cmnr144ay048dp658iznka25r", "runId": "cmnr144av0488p658z3pgf0fh", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-06T20:00:02.000Z\",\n \"ticker\": \"HOLX\",\n \"currency\": \"USD\",\n \"current_price\": 76.01,\n \"target_price_6m\": 77.0,\n \"target_price_12m\": 78.0,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"Stable revenue growth in women's health markets.\",\n \"Strong operating and net margins support cash flow.\",\n \"Moderate EPS growth driven by margin improvements.\",\n \"Valuation appears fair relative to forward P/E.\",\n \"Balanced bull-bear scenarios with limited upside.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"New product launches in diagnostics\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Cost efficiency and margin expansion\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory approvals for medical devices\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Competitive pressure in medical tech\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Macroeconomic impact on healthcare spending\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Debt management and interest rate exposure\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"EPS growth from operational leverage\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Market share gains in core segments\", \"impact\": \"HIGH\", \"direction\": \"POS\" }\n ],\n \"risks\": [\"Regulatory hurdles for new products\", \"Intense industry competition\", \"Economic downturns reducing demand\", \"Potential product recalls or lawsuits\", \"Currency fluctuations affecting international sales\"],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.23,\n \"wacc\": 0.08,\n \"terminal_multiple\": 15\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 63.31, \"prob\": 0.3, \"notes\": \"Lower growth and multiple contraction due to competitive pressures.\" },\n \"base\": { \"target_price\": 78.0, \"prob\": 0.5, \"notes\": \"Moderate EPS growth and stable valuation multiples.\" },\n \"bull\": { \"target_price\": 90.05, \"prob\": 0.2, \"notes\": \"Higher growth and multiple expansion from successful product launches.\" }\n },\n \"method_notes\": \"DCF with assumed 5% revenue CAGR and 23% EBIT margin; HOLD as 12M expected return ~2.6% with balanced evidence. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-06T20:00:02.000Z", "model": "AI Equity Research Model", "risks": [ "Regulatory hurdles for new products", "Intense industry competition", "Economic downturns reducing demand", "Potential product recalls or lawsuits", "Currency fluctuations affecting international sales" ], "ticker": "HOLX", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Moderate EPS growth and stable valuation multiples.", "target_price": 78 }, "bear": { "prob": 0.3, "notes": "Lower growth and multiple contraction due to competitive pressures.", "target_price": 63.31 }, "bull": { "prob": 0.2, "notes": "Higher growth and multiple expansion from successful product launches.", "target_price": 90.05 } }, "confidence": 0.6, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.05, "terminal_multiple": 15, "ebit_margin_target": 0.23 }, "key_drivers": [ { "driver": "New product launches in diagnostics", "impact": "MED", "direction": "POS" }, { "driver": "Cost efficiency and margin expansion", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory approvals for medical devices", "impact": "HIGH", "direction": "POS" }, { "driver": "Competitive pressure in medical tech", "impact": "MED", "direction": "NEG" }, { "driver": "Macroeconomic impact on healthcare spending", "impact": "LOW", "direction": "NEG" }, { "driver": "Debt management and interest rate exposure", "impact": "LOW", "direction": "NEG" }, { "driver": "EPS growth from operational leverage", "impact": "MED", "direction": "POS" }, { "driver": "Market share gains in core segments", "impact": "HIGH", "direction": "POS" } ], "method_notes": "DCF with assumed 5% revenue CAGR and 23% EBIT margin; HOLD as 12M expected return ~2.6% with balanced evidence. Not investment advice.", "current_price": 76.01, "recommendation": "HOLD", "thesis_bullets": [ "Stable revenue growth in women's health markets.", "Strong operating and net margins support cash flow.", "Moderate EPS growth driven by margin improvements.", "Valuation appears fair relative to forward P/E.", "Balanced bull-bear scenarios with limited upside." ], "target_price_6m": 77, "target_price_12m": 78 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 386, "createdAt": "2026-04-09T05:21:02.405Z", "usage": { "inputTokens": 2064, "outputTokens": 4326, "costUsd": 0.002395 } }, { "id": "cmnr144ay048bp658yc6i942s", "runId": "cmnr144av0488p658z3pgf0fh", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Model Recommendation\",\n \"as_of\": \"2026-04-06T20:00:02.000Z\",\n \"ticker\": \"HOLX\",\n \"currency\": \"USD\",\n \"current_price\": 76.01,\n \"target_price_6m\": 82.00,\n \"target_price_12m\": 88.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.80,\n \"thesis_bullets\": [\n \"Strong FCF generation supports aggressive share repurchases and accretive M&A.\",\n \"Breast Health segment benefits from a steady 3D mammography upgrade cycle.\",\n \"Surgical division offers high-margin growth, diversifying away from legacy diagnostics.\",\n \"Defensive profile with low beta (0.75) and a highly robust balance sheet.\",\n \"Valuation remains attractive at ~16x FCF despite trading near 52-week highs.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Breast Health upgrade cycle\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Surgical segment expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Hospital CapEx budgets\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Share repurchase program\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Diagnostics base volume\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"FX fluctuations\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Prolonged hospital capital equipment spending constraints.\",\n \"Increased competition in molecular diagnostics.\",\n \"Supply chain disruptions affecting imaging equipment deliveries.\",\n \"Regulatory delays for new product approvals.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.045,\n \"ebit_margin_target\": 0.24,\n \"wacc\": 0.075,\n \"terminal_multiple\": 16.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 65.00,\n \"prob\": 0.25,\n \"notes\": \"Hospital CapEx freezes and margin compression drive multiple contraction.\"\n },\n \"base\": {\n \"target_price\": 88.00,\n \"prob\": 0.60,\n \"notes\": \"Steady growth in surgical/breast health and consistent share buybacks.\"\n },\n \"bull\": {\n \"target_price\": 105.00,\n \"prob\": 0.15,\n \"notes\": \"Accretive M&A and faster adoption of new imaging tech expand multiples.\"\n }\n },\n \"method_notes\": \"Valuation based on a blend of DCF and EV/FCF multiples. The 12M target of $88 implies a ~15.7% upside, supporting a BUY rating. Strong FCF yield (~7.7%) provides a margin of safety. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-06T20:00:02.000Z", "model": "AI Model Recommendation", "risks": [ "Prolonged hospital capital equipment spending constraints.", "Increased competition in molecular diagnostics.", "Supply chain disruptions affecting imaging equipment deliveries.", "Regulatory delays for new product approvals." ], "ticker": "HOLX", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady growth in surgical/breast health and consistent share buybacks.", "target_price": 88 }, "bear": { "prob": 0.25, "notes": "Hospital CapEx freezes and margin compression drive multiple contraction.", "target_price": 65 }, "bull": { "prob": 0.15, "notes": "Accretive M&A and faster adoption of new imaging tech expand multiples.", "target_price": 105 } }, "confidence": 0.8, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.045, "terminal_multiple": 16, "ebit_margin_target": 0.24 }, "key_drivers": [ { "driver": "Breast Health upgrade cycle", "impact": "HIGH", "direction": "POS" }, { "driver": "Surgical segment expansion", "impact": "MED", "direction": "POS" }, { "driver": "Hospital CapEx budgets", "impact": "HIGH", "direction": "NEG" }, { "driver": "Share repurchase program", "impact": "MED", "direction": "POS" }, { "driver": "Diagnostics base volume", "impact": "MED", "direction": "POS" }, { "driver": "FX fluctuations", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation based on a blend of DCF and EV/FCF multiples. The 12M target of $88 implies a ~15.7% upside, supporting a BUY rating. Strong FCF yield (~7.7%) provides a margin of safety. Not investment advice.", "current_price": 76.01, "recommendation": "BUY", "thesis_bullets": [ "Strong FCF generation supports aggressive share repurchases and accretive M&A.", "Breast Health segment benefits from a steady 3D mammography upgrade cycle.", "Surgical division offers high-margin growth, diversifying away from legacy diagnostics.", "Defensive profile with low beta (0.75) and a highly robust balance sheet.", "Valuation remains attractive at ~16x FCF despite trading near 52-week highs." ], "target_price_6m": 82, "target_price_12m": 88 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 29270, "createdAt": "2026-04-09T05:21:02.405Z", "usage": { "inputTokens": 2409, "outputTokens": 810, "costUsd": 0.014538 } }, { "id": "cmnr144ay0489p658dbr06jt3", "runId": "cmnr144av0488p658z3pgf0fh", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"OpenAI o3\",\"as_of\":\"2026-04-06T20:00:02.000Z\",\"ticker\":\"HOLX\",\"currency\":\"USD\",\"current_price\":76.01,\"target_price_6m\":78.5,\"target_price_12m\":80,\"recommendation\":\"HOLD\",\"confidence\":0.58,\"thesis_bullets\":[\"Women's health franchise supports resilient recurring demand.\",\"Diagnostics and breast health mix underpins solid margins.\",\"Strong free cash flow and liquidity provide strategic flexibility.\",\"Revenue growth remains modest, limiting multiple expansion.\",\"Shares near highs look close to fair value absent reacceleration.\"],\"key_drivers\":[{\"driver\":\"Breast screening demand\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Diagnostics utilization\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Margin discipline\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Cash deployment\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Procedure volume softness\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Reimbursement changes\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Regulatory execution\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Full valuation\",\"impact\":\"HIGH\",\"direction\":\"NEG\"}],\"risks\":[\"Slower screening or diagnostics volumes.\",\"Reimbursement or regulatory pressure.\",\"Product quality, litigation, or recall costs.\",\"M&A integration or capital allocation missteps.\",\"Hospital budget constraints delay equipment purchases.\"],\"assumptions\":{\"revenue_cagr_3y\":0.05,\"ebit_margin_target\":0.27,\"wacc\":0.09,\"terminal_multiple\":17},\"scenarios\":{\"bear\":{\"target_price\":66,\"prob\":0.25,\"notes\":\"Volume softness and lower placements compress margins and multiples.\"},\"base\":{\"target_price\":80,\"prob\":0.5,\"notes\":\"Low-single-digit growth and stable margins support roughly fair value.\"},\"bull\":{\"target_price\":90,\"prob\":0.25,\"notes\":\"Better diagnostics momentum and mix lift earnings and rerating.\"}},\"method_notes\":\"Snapshot fields used for quote inputs. Valuation triangulates forward earnings and EV/EBIT-style assumptions; recommendation is HOLD because 12M upside vs current price is ~5% and evidence is mixed. Snapshot fundamentals show some internal inconsistencies, so confidence is moderate. No sell-side targets used; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-06T20:00:02.000Z", "model": "OpenAI o3", "risks": [ "Slower screening or diagnostics volumes.", "Reimbursement or regulatory pressure.", "Product quality, litigation, or recall costs.", "M&A integration or capital allocation missteps.", "Hospital budget constraints delay equipment purchases." ], "ticker": "HOLX", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Low-single-digit growth and stable margins support roughly fair value.", "target_price": 80 }, "bear": { "prob": 0.25, "notes": "Volume softness and lower placements compress margins and multiples.", "target_price": 66 }, "bull": { "prob": 0.25, "notes": "Better diagnostics momentum and mix lift earnings and rerating.", "target_price": 90 } }, "confidence": 0.58, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.05, "terminal_multiple": 17, "ebit_margin_target": 0.27 }, "key_drivers": [ { "driver": "Breast screening demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Diagnostics utilization", "impact": "MED", "direction": "POS" }, { "driver": "Margin discipline", "impact": "HIGH", "direction": "POS" }, { "driver": "Cash deployment", "impact": "MED", "direction": "POS" }, { "driver": "Procedure volume softness", "impact": "MED", "direction": "NEG" }, { "driver": "Reimbursement changes", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory execution", "impact": "MED", "direction": "NEG" }, { "driver": "Full valuation", "impact": "HIGH", "direction": "NEG" } ], "method_notes": "Snapshot fields used for quote inputs. Valuation triangulates forward earnings and EV/EBIT-style assumptions; recommendation is HOLD because 12M upside vs current price is ~5% and evidence is mixed. Snapshot fundamentals show some internal inconsistencies, so confidence is moderate. No sell-side targets used; not investment advice.", "current_price": 76.01, "recommendation": "HOLD", "thesis_bullets": [ "Women's health franchise supports resilient recurring demand.", "Diagnostics and breast health mix underpins solid margins.", "Strong free cash flow and liquidity provide strategic flexibility.", "Revenue growth remains modest, limiting multiple expansion.", "Shares near highs look close to fair value absent reacceleration." ], "target_price_6m": 78.5, "target_price_12m": 80 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_0242ad1e2aea58c10069d759c2f8b88196895dc2b0e78c1f50", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 35906, "createdAt": "2026-04-09T05:21:02.405Z", "usage": { "inputTokens": 2337, "outputTokens": 1828, "costUsd": 0.029682 } }, { "id": "cmnr144ay048cp658yvll9zpj", "runId": "cmnr144av0488p658z3pgf0fh", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model\",\n \"as_of\": \"2026-04-06T20:00:02.000Z\",\n \"ticker\": \"HOLX\",\n \"currency\": \"USD\",\n \"current_price\": 76.01,\n \"target_price_6m\": 82,\n \"target_price_12m\": 87,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Strong position in women's health diagnostics and imaging\",\n \"Robust EPS growth of 81% YOY shows operational leverage\",\n \"High valuation near 52-week highs caps near-term gains\",\n \"Solid balance sheet supports M&A and R&D investments\",\n \"Preventive care trends offer long-term demand tailwinds\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Women's health demand\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Diagnostic innovation\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"EBIT margin expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"M&A using cash reserves\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Elevated current valuation\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Competitor pressure in imaging\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Regulatory product approvals\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Hospital capex slowdown\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Intensifying competition in diagnostics\",\n \"FDA delays on new devices\",\n \"Reduced hospital procedure volumes\",\n \"Acquisition integration challenges\",\n \"Macro impact on healthcare budgets\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.24,\n \"wacc\": 0.085,\n \"terminal_multiple\": 17\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 62,\n \"prob\": 0.3,\n \"notes\": \"Growth stalls amid competition and spending cuts.\"\n },\n \"base\": {\n \"target_price\": 87,\n \"prob\": 0.5,\n \"notes\": \"Steady execution on innovation and margins.\"\n },\n \"bull\": {\n \"target_price\": 105,\n \"prob\": 0.2,\n \"notes\": \"Accelerated adoption and successful M&A.\"\n }\n },\n \"method_notes\": \"DCF using assumed 5% revenue CAGR, 24% EBIT margin, 8.5% WACC and 17x terminal multiple. 12M target implies ~14% upside matching BUY per rubric on growth/margin support despite high valuation. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-06T20:00:02.000Z", "model": "AI Equity Research Model", "risks": [ "Intensifying competition in diagnostics", "FDA delays on new devices", "Reduced hospital procedure volumes", "Acquisition integration challenges", "Macro impact on healthcare budgets" ], "ticker": "HOLX", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady execution on innovation and margins.", "target_price": 87 }, "bear": { "prob": 0.3, "notes": "Growth stalls amid competition and spending cuts.", "target_price": 62 }, "bull": { "prob": 0.2, "notes": "Accelerated adoption and successful M&A.", "target_price": 105 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.05, "terminal_multiple": 17, "ebit_margin_target": 0.24 }, "key_drivers": [ { "driver": "Women's health demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Diagnostic innovation", "impact": "HIGH", "direction": "POS" }, { "driver": "EBIT margin expansion", "impact": "MED", "direction": "POS" }, { "driver": "M&A using cash reserves", "impact": "MED", "direction": "POS" }, { "driver": "Elevated current valuation", "impact": "HIGH", "direction": "NEG" }, { "driver": "Competitor pressure in imaging", "impact": "MED", "direction": "NEG" }, { "driver": "Regulatory product approvals", "impact": "MED", "direction": "POS" }, { "driver": "Hospital capex slowdown", "impact": "LOW", "direction": "NEG" } ], "method_notes": "DCF using assumed 5% revenue CAGR, 24% EBIT margin, 8.5% WACC and 17x terminal multiple. 12M target implies ~14% upside matching BUY per rubric on growth/margin support despite high valuation. Not investment advice.", "current_price": 76.01, "recommendation": "BUY", "thesis_bullets": [ "Strong position in women's health diagnostics and imaging", "Robust EPS growth of 81% YOY shows operational leverage", "High valuation near 52-week highs caps near-term gains", "Solid balance sheet supports M&A and R&D investments", "Preventive care trends offer long-term demand tailwinds" ], "target_price_6m": 82, "target_price_12m": 87 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "ecc1e991-cb09-9cd7-9416-c1c811761182", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 20089, "createdAt": "2026-04-09T05:21:02.405Z", "usage": { "inputTokens": 2674, "outputTokens": 3312, "costUsd": 0.057702 } } ] } }